Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Renal Failure
  Free Subscription

Articles published in
Curr Opin Nephrol Hypertens
    July 2026
  1. STRAIN S, Crowley L
    Multimorbidity after renal transplantation: incidence and implications for patients.
    Curr Opin Nephrol Hypertens. 2026 Jul 17. doi: 10.1097/MNH.0000000000001213.
    >> Share

    June 2026
  2. WANIGATUNGA M, Holliday MW, Navaneethan SD
    Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.
    Curr Opin Nephrol Hypertens. 2026 Jun 16. doi: 10.1097/MNH.0000000000001205.
    >> Share

  3. SILVARINO R, Sola L
    Social determinants of chronic kidney disease: from association to clinical and population action.
    Curr Opin Nephrol Hypertens. 2026 Jun 9. doi: 10.1097/MNH.0000000000001201.
    >> Share

    April 2026
  4. JORGETTI V, Dos Reis LM, Ferreira A
    A need for normalization of bone histomorphometry parameters in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2026 Apr 30. doi: 10.1097/MNH.0000000000001189.
    >> Share

  5. GUTIERREZ OM
    Recent insights into the role of dietary phosphorus in the development and progression of chronic kidney disease-mineral and bone disorder.
    Curr Opin Nephrol Hypertens. 2026 Apr 30. doi: 10.1097/MNH.0000000000001185.
    >> Share

    March 2026
  6. CLAUDEL SE, Waikar SS, Scammell MK
    An update on the epidemiology of chronic kidney disease of uncertain etiology.
    Curr Opin Nephrol Hypertens. 2026 Mar 17. doi: 10.1097/MNH.0000000000001177.
    >> Share

  7. MAZZIERI A, Battistoni S, Reboldi G
    Aldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?
    Curr Opin Nephrol Hypertens. 2026 Mar 12. doi: 10.1097/MNH.0000000000001175.
    >> Share

  8. RHEE CM, Zisman-Ilani Y, Kalantar-Zadeh K, Nguyen DV, et al
    Continuous glucose monitoring in patients with chronic kidney disease on dialysis and with kidney transplantation.
    Curr Opin Nephrol Hypertens. 2026 Mar 6. doi: 10.1097/MNH.0000000000001169.
    >> Share

    January 2026
  9. SHAH AD, Goldfarb DS
    Hemodiafiltration: balancing clinical efficacy with planetary health.
    Curr Opin Nephrol Hypertens. 2026 Jan 9. doi: 10.1097/MNH.0000000000001160.
    >> Share

  10. SAEED F, Duberstein PR, White DB, Liu KD, et al
    Time-limited trials for acute dialysis decision-making for critically ill older patients: rationale, communication strategies, and future research.
    Curr Opin Nephrol Hypertens. 2026 Jan 6. doi: 10.1097/MNH.0000000000001155.
    >> Share

  11. SHAH AD
    Home sweet home dialysis.
    Curr Opin Nephrol Hypertens. 2026;35:72-73.
    >> Share

    December 2025
  12. HERNANDEZ MF, Chang TI
    Pros and cons of lower blood pressure targets in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 Dec 30. doi: 10.1097/MNH.0000000000001153.
    >> Share

  13. RATTANASOMPATTIKUL M, Srithongkul T, Tantisattamo E, Kalantar-Zadeh K, et al
    Indoxyl sulfate: clinical implications for anemia management in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 Dec 8. doi: 10.1097/MNH.0000000000001145.
    >> Share

    November 2025
  14. ZISMAN-ILANI Y, Rhee CM, Ammary FA, Kalantar-Zadeh K, et al
    Shared decision making and decision aids in the management of kidney disease and renal replacement treatment options.
    Curr Opin Nephrol Hypertens. 2025 Nov 24. doi: 10.1097/MNH.0000000000001140.
    >> Share

  15. DAI T, Shah A, Chong CC, Pham PC, et al
    Evolution of continuous renal replacement therapy scenarios and the rise of anticoagulant-free continuous veno-venous hemodiafiltration.
    Curr Opin Nephrol Hypertens. 2025 Nov 20. doi: 10.1097/MNH.0000000000001138.
    >> Share

  16. TAKAHASHI R, Obi Y, Kalantar-Zadeh K, Kovesdy CP, et al
    The obesity and lipid paradoxes in chronic kidney disease: mechanisms, interventions, and future directions.
    Curr Opin Nephrol Hypertens. 2025 Nov 20. doi: 10.1097/MNH.0000000000001131.
    >> Share

  17. TAKASHIMA H, Maruyama T, Abe M
    Super high-flux membrane dialyzers and mortality in patients undergoing hemodialysis.
    Curr Opin Nephrol Hypertens. 2025 Nov 11. doi: 10.1097/MNH.0000000000001134.
    >> Share

  18. NERI L, Zhang H, Usvyat LA
    Artificial intelligence in kidney disease and dialysis: from data mining to clinical impact.
    Curr Opin Nephrol Hypertens. 2025 Nov 10. doi: 10.1097/MNH.0000000000001132.
    >> Share

    October 2025
  19. HUSSEIN WF, Abra G
    Staff-assisted peritoneal dialysis in the United States: from evidence to national adoption.
    Curr Opin Nephrol Hypertens. 2025 Oct 30. doi: 10.1097/MNH.0000000000001128.
    >> Share

  20. CADORE-GUZZO E, Baptise T, Shah A
    Back to the future: a review of peritoneal dialysis for acute kidney injury.
    Curr Opin Nephrol Hypertens. 2025 Oct 30. doi: 10.1097/MNH.0000000000001129.
    >> Share

  21. BANSAL S, Nararyan R
    Management of peritoneal dialysis in patients with obesity.
    Curr Opin Nephrol Hypertens. 2025 Oct 24. doi: 10.1097/MNH.0000000000001124.
    >> Share

  22. EL SHAMY O
    Remote monitoring in peritoneal dialysis: an underutilized tool.
    Curr Opin Nephrol Hypertens. 2025 Oct 23. doi: 10.1097/MNH.0000000000001127.
    >> Share

  23. BERMUDEZ MC, El Shamy O
    Self-cannulation for home hemodialysis: a review of current practices and implementation approaches.
    Curr Opin Nephrol Hypertens. 2025 Oct 15. doi: 10.1097/MNH.0000000000001121.
    >> Share

  24. HSU CM, Weiner DE, McCallum W
    Peritoneal dialysis and heart failure.
    Curr Opin Nephrol Hypertens. 2025 Oct 15. doi: 10.1097/MNH.0000000000001125.
    >> Share

  25. YE WWQ, Malavade T, Bargman JM, Chan CT, et al
    Bringing medical education "home": the university health network and St. Michael's hospital home dialysis fellowship.
    Curr Opin Nephrol Hypertens. 2025 Oct 6. doi: 10.1097/MNH.0000000000001122.
    >> Share

    September 2025
  26. MERLINO L, Tollitt J, Dunne RA, Kalra PA, et al
    Pathophysiology of cognitive impairment in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 Sep 15. doi: 10.1097/MNH.0000000000001117.
    >> Share

    July 2025
  27. LIARAKOS AL, Randhay A, Wilmot EG
    Continuous glucose monitoring and automated insulin delivery systems in the management of diabetes among individuals with chronic kidney disease on dialysis.
    Curr Opin Nephrol Hypertens. 2025 Jul 15. doi: 10.1097/MNH.0000000000001106.
    >> Share

  28. SKOBERNE A
    The impact of conflicts on patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 Jul 15. doi: 10.1097/MNH.0000000000001107.
    >> Share

    May 2025
  29. KHAIRALLAH P
    Agents to treat osteoporosis in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 May 19. doi: 10.1097/MNH.0000000000001091.
    >> Share

  30. DELANAYE P, Gama RM, Stehle T
    Impact of the choice of biomarkers and equations to estimate kidney function on the epidemiology of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 May 19. doi: 10.1097/MNH.0000000000001085.
    >> Share

  31. POTHULA VENKATA V, Scialla JJ
    Momentum toward patient outcome trials in chronic kidney disease-mineral bone disorder.
    Curr Opin Nephrol Hypertens. 2025 May 19. doi: 10.1097/MNH.0000000000001087.
    >> Share

  32. ABU KAR S, Harris RC
    Chronic kidney disease and sex dimorphism.
    Curr Opin Nephrol Hypertens. 2025 May 15. doi: 10.1097/MNH.0000000000001093.
    >> Share

  33. THEODORAKOPOULOU MP, Iatridi F, Sarafidis PA
    Aldosterone synthase inhibition in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 May 2. doi: 10.1097/MNH.0000000000001089.
    >> Share

  34. FREIRE-FILHO WA, Dalboni MA, Elias RM
    Effects of aging on chronic kidney disease mineral and bone disorder.
    Curr Opin Nephrol Hypertens. 2025 May 2. doi: 10.1097/MNH.0000000000001084.
    >> Share

    April 2025
  35. MARTINEZ-ROJAS MA, Bobadilla NA
    Sodium-glucose cotransporter 2 inhibitors: a novel approach to prevent the transition from acute kidney injury to chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025 Apr 23. doi: 10.1097/MNH.0000000000001080.
    >> Share

  36. SPENCER S, Bhandari S
    Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.
    Curr Opin Nephrol Hypertens. 2025 Apr 8. doi: 10.1097/MNH.0000000000001076.
    >> Share

  37. DUQUE EJ, Giachelli C, Moyses RMA
    The role of osteopontin in chronic kidney disease-mineral bone disorder.
    Curr Opin Nephrol Hypertens. 2025 Apr 2. doi: 10.1097/MNH.0000000000001074.
    >> Share

    March 2025
  38. GOLDFARB DS
    The hemodialysis unit: the place where everybody knows your name.
    Curr Opin Nephrol Hypertens. 2025;34:129-130.
    >> Share

    February 2025
  39. LEDUC C, Tomisawa N, Ronco C, Kalantar-Zadeh K, et al
    The history and future of online hemodiafiltration and online solutions in North America.
    Curr Opin Nephrol Hypertens. 2025 Feb 19. doi: 10.1097/MNH.0000000000001051.
    >> Share

    January 2025
  40. RHEE CM, Kovesdy CP, Unruh M, Crowley S, et al
    Incremental hemodialysis transition in veterans and nonveterans with kidney failure.
    Curr Opin Nephrol Hypertens. 2025;34:33-40.
    >> Share

  41. TANTISATTAMO E, Hanna RM, Kalantar-Zadeh K
    Implementing novel diagnostic and therapeutic strategies to improve population health outcomes and equity in kidney disease, dialysis therapies, and transplantation.
    Curr Opin Nephrol Hypertens. 2025;34:1-3.
    >> Share

  42. YERRAM P, Edwards D, Norris KC, Molony D, et al
    Practicing health equity in kidney care by establishing improved access to timely disease management and kidney replacement therapy options: from providers to patients.
    Curr Opin Nephrol Hypertens. 2025;34:48-54.
    >> Share

  43. SEGHERS F, Tintillier M, Morelle J
    Recent advances in the understanding of the peritoneal membrane.
    Curr Opin Nephrol Hypertens. 2025;34:77-84.
    >> Share

  44. SHAH AD
    Bringing the end-stage kidney disease life plan home.
    Curr Opin Nephrol Hypertens. 2025;34:67-68.
    >> Share

  45. NARASAKI Y, Rhee CM, Kalantar-Zadeh K, Rastegar M, et al
    Why protein-energy wasting leads to faster progression of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2025;34:55-66.
    >> Share

  46. BROWN CO, Pham PC, Shah A, Dukkipati R, et al
    Population health strategies for health equity in chronic kidney disease management.
    Curr Opin Nephrol Hypertens. 2025;34:41-47.
    >> Share

    December 2024
  47. MARTIN D, Brewster P, Crowley ST
    Preparing for stormy weather: building VA health system resilience for dialysis emergency preparedness in the era of climate change.
    Curr Opin Nephrol Hypertens. 2024 Dec 18. doi: 10.1097/MNH.0000000000001054.
    >> Share

  48. WATNICK S
    Use of water in dialysis and its impact on the environment.
    Curr Opin Nephrol Hypertens. 2024 Dec 18. doi: 10.1097/MNH.0000000000001058.
    >> Share

  49. WALLACH JD, Medaura JA, Stern L
    Home dialysis: there's no place like home.
    Curr Opin Nephrol Hypertens. 2024 Dec 16. doi: 10.1097/MNH.0000000000001056.
    >> Share


  50. Population Health Strategies for Health Equity in Chronic Kidney Disease Management: Retraction.
    Curr Opin Nephrol Hypertens. 2024 Dec 10. doi: 10.1097/MNH.0000000000001055.
    >> Share

    November 2024
  51. KIM B, Kanchi R, Titus AR, Grams ME, et al
    Built environment and chronic kidney disease: current state and future directions.
    Curr Opin Nephrol Hypertens. 2024 Nov 22. doi: 10.1097/MNH.0000000000001048.
    >> Share

  52. BROWN CO, Pham PC, Shah A, Dukkipati R, et al
    Population health strategies for health equity in chronic kidney disease management.
    Curr Opin Nephrol Hypertens. 2024 Nov 21. doi: 10.1097/MNH.0000000000001044.
    >> Share

  53. SHRINGI S, Shah AD
    The cardiovascular unphysiology of thrice weekly hemodialysis.
    Curr Opin Nephrol Hypertens. 2024 Nov 6. doi: 10.1097/MNH.0000000000001037.
    >> Share

  54. PECCE A, Belhumeur L, Nadeau-Fredette AC
    Staying home when peritoneal dialysis ends: the integrated home dialysis approach.
    Curr Opin Nephrol Hypertens. 2024 Nov 4. doi: 10.1097/MNH.0000000000001034.
    >> Share

    October 2024
  55. SHAMY OE, Sloand JA
    Automation and innovation in home hemodialysis machines.
    Curr Opin Nephrol Hypertens. 2024 Oct 30. doi: 10.1097/MNH.0000000000001033.
    >> Share

  56. AL SAHLAWI M, Chan CT, Perl J
    Infection prevention in home dialysis.
    Curr Opin Nephrol Hypertens. 2024 Oct 15. doi: 10.1097/MNH.0000000000001032.
    >> Share

  57. QUINN RR, Oliver MJ
    Recent advances in peritoneal dialysis catheter placement: the association between method of insertion, operator, and prior abdominal surgery and outcomes.
    Curr Opin Nephrol Hypertens. 2024 Oct 7. doi: 10.1097/MNH.0000000000001031.
    >> Share

    September 2024
  58. IYENGAR A, Kalyesubula R, Darwish R, Luyckx VA, et al
    International equity in access to home dialysis.
    Curr Opin Nephrol Hypertens. 2024 Sep 13. doi: 10.1097/MNH.0000000000001027.
    >> Share

    August 2024
  59. VAN MIL D, Kieneker LM, Heerspink HJL, Gansevoort RT, et al
    Screening for chronic kidney disease: change of perspective and novel developments.
    Curr Opin Nephrol Hypertens. 2024 Aug 14. doi: 10.1097/MNH.0000000000001016.
    >> Share

  60. PEPIN M, Levassort H, Massy ZA
    The impact of chronic kidney disease on cognitive function.
    Curr Opin Nephrol Hypertens. 2024 Aug 13. doi: 10.1097/MNH.0000000000001017.
    >> Share

    July 2024
  61. FRASER SDS, Phillips T
    Quality of life in people with chronic kidney disease: focusing on modifiable risk factors.
    Curr Opin Nephrol Hypertens. 2024 Jul 23. doi: 10.1097/MNH.0000000000001013.
    >> Share

  62. DANZIGER J
    Synergistic susceptibility to environmental lead toxicity in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2024 Jul 18. doi: 10.1097/MNH.0000000000000991.
    >> Share

    June 2024
  63. TUTTLE M, Sarnak MJ, Navaneethan SD
    Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2024 Jun 20. doi: 10.1097/MNH.0000000000001008.
    >> Share

    April 2024
  64. EVENEPOEL P, Jorgensen HS
    Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2024 Apr 24. doi: 10.1097/MNH.0000000000000992.
    >> Share

  65. FAIVRE A, de Seigneux S
    The role of hypoxia in chronic kidney disease: a nuanced perspective.
    Curr Opin Nephrol Hypertens. 2024 Apr 11. doi: 10.1097/MNH.0000000000000989.
    >> Share

  66. HUISH S, Sinha S
    New therapeutic perspectives for vascular and valvular calcifications in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2024 Apr 5. doi: 10.1097/MNH.0000000000000985.
    >> Share

    March 2024
  67. ALEXIUK M, Tangri N
    Prediction models for earlier stages of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2024 Mar 1. doi: 10.1097/MNH.0000000000000981.
    >> Share

    February 2024
  68. HOLLIDAY MW JR, Frost L, Navaneethan SD
    Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.
    Curr Opin Nephrol Hypertens. 2024 Feb 26. doi: 10.1097/MNH.0000000000000976.
    >> Share

  69. HUNDEMER GL, Akbari A, Sood MM
    Has the time come for age-adapted glomerular filtration rate criteria to define chronic kidney disease: how soon is now?
    Curr Opin Nephrol Hypertens. 2024 Feb 26. doi: 10.1097/MNH.0000000000000971.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016